echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Fujian "4 plus 7" renewal when the open inquiry stage lipeone flow standard

    Fujian "4 plus 7" renewal when the open inquiry stage lipeone flow standard

    • Last Update: 2020-05-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Wen FengqiuMay 19, Fujian Provincial Health Insurance Bureau announced the "part of the 4 plus 7 pilot drug public inquiry to choose the results", Qilu Pharmaceutical's atofalastin calcium tablets through the public inquiry to obtain the proposed qualification, Lipei ketone tablets are the standardOn May 7, Fujian Province began to follow up the "4 plus 7" renewal workAccording to the renewal document rules, atovastatin tablets and lipeone tablets two varieties due to "4 plus 7" and the expansion of the lowest-priced enterprises do not agree to renew, then not higher than the average price of the expansion of the public inquiry to expand the selection of enterprises, take the lowest price contractin the "4 plus 7" pilot band procurement, Huahai Pharmaceuticals to 10.02 yuan / box price, and then at 7.2 yuan / box price in the expansion of the bidIn the "4 plus 7" city renewal process, Huahai Pharmaceuticals also to expand the price in most cities to obtain the renewal qualificationAnd Lipeketone tablets in the "4 plus 7" expansion of the winning enterprises a total of 3, respectively, Qilu Pharmaceuticals (0.049 yuan / tablet), Changzhou four drugs (0.12 yuan / tablet), Huahai Pharmaceuticals (0.12 yuan / tablet)Qilu Pharmaceuticals successfully won the bid in the open inquiry process for atoflavatin tablets, but waived the renewal of the opioid, resulting in the spread of lipitone in the public inquiryAccording to the renewal rules of Fujian Province, no enterprise should bid when the public inquiry is made, then the enterprise with the lowest-to-high rank edgy-ranked second-and-third-place enterprises shall make an inquiry according to the selected price of the enterprise's expansionFollow-up results are likely to be announced in the near future
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.